Carcinoid syndrome management market seen topping $2.9 billion by 2030

The carcinoid syndrome management market is forecast to grow from $1.96 billion in 2025 to $2.92 billion by 2030 as cancer diagnoses rise and oncology tools improve. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Carcinoid syndrome management sits at the intersection of rare cancer care and broader oncology demand. - Growth in the market reflects rising need for therapies that ease flushing, diarrhea, wheezing and abdominal pain in patients with hormone-secreting neuroendocrine tumors. - The market’s expansion also tracks the global cancer burden, which is pushing health systems to improve diagnosis, symptom control and long-term care.

What happened: - The Business Research Company released its Carcinoid Syndrome Management Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report pegs the market at $1.96 billion in 2025 and $2.12 billion in 2026. - The report forecasts the market will reach $2.92 billion by 2030. - The report was published Sept. 5, 2026, in London. - A free sample report is available. - The full market report is also available.

The details: - The report says recent growth has been supported by better diagnosis of neuroendocrine tumors. - Wider recognition of carcinoid syndrome symptoms has helped lift demand. - Hospital oncology services are expanding their scope. - Somatostatin analogues are being used more widely. - Access to advanced cancer imaging is improving. - The forecast through 2030 points to an 8.3% CAGR from 2026 to 2030. - Expected growth drivers include precision oncology, biomarker discovery, more funding for rare cancer studies, targeted and immunotherapy adoption, clinical trials in radiopharmaceutical therapies and personalized oncology protocols. - The report flags broader use of targeted biologics for symptom control. - It also points to personalized care for neuroendocrine tumors, minimally invasive surgeries, radiopharmaceutical interventions for late-stage patients and combination therapies.

Between the lines: - The market outlook suggests carcinoid syndrome is becoming a more visible segment within oncology rather than a niche clinical problem. - The emphasis on biomarkers, targeted therapy and radiopharmaceuticals signals a shift toward more precise treatment approaches. - WHO projections cited in the report show why cancer-related markets continue to draw attention: global new cancer cases could top 35 million by 2050, up 77% from about 20 million in 2022. - North America’s lead likely reflects its established healthcare infrastructure and advanced oncology services. - Asia-Pacific’s faster growth points to improving access to care, higher awareness and more cancer-care investment.

What's next: - The report expects market momentum to continue as oncology innovation broadens treatment options. - Clinical trial activity in radiopharmaceutical therapies should remain a watchpoint. - Personalized protocols and combination regimens are likely to shape the next phase of care. - The report includes updated graphics, tables, TAM analysis, market attractiveness scoring, company scoring matrix visuals and Excel-based forecasting dashboards. - Other regions covered include South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

The bottom line: - Carcinoid syndrome management is moving into a faster-growth phase as cancer prevalence rises and treatment approaches become more targeted.